[1]何斌 张冬颖.阿司匹林一级预防的研究进展[J].心血管病学进展,2020,(6):627.[doi:10.16806/j.cnki.issn.1004-3934.20.06.016]
 HE Bin,ZHANG Dongying.Primary Prevention of Aspirin[J].Advances in Cardiovascular Diseases,2020,(6):627.[doi:10.16806/j.cnki.issn.1004-3934.20.06.016]
点击复制

阿司匹林一级预防的研究进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年6期
页码:
627
栏目:
综述
出版日期:
2020-06-25

文章信息/Info

Title:
Primary Prevention of Aspirin
作者:
何斌 张冬颖
(重庆医科大学附属第一医院心血管内科,重庆 400016)
Author(s):
HE Bin ZHANG Dongying
(Department of Cardiology,The First Affiliated Hospital of Chongqing Medical Universiy,Chongqing 400016,China)
关键词:
心血管疾病阿司匹林一级预防
Keywords:
Cardiovascular disease Aspirin Primary prevention
DOI:
10.16806/j.cnki.issn.1004-3934.20.06.016
摘要:
阿司匹林通过抑制环氧化酶阻断血栓烷A2生成而发挥抗血小板聚集作用。已有临床证据证明阿司匹林可减少冠状动脉急性事件发生,起到心血管疾病一级预防作用。阿司匹林的心血管疾病二级预防地位已得到肯定,一级预防作用尚存在争议。现对近期有关阿司匹林在一级预防的试验和进展进行综述,以期为临床阿司匹林应用提供参考。
Abstract:
Aspirin can inhibit platelet aggregation by inhibiting the production of thromboxane A2 by cyclooxygenase. There is clinical evidence that aspirin can reduce the occurrence of acute coronary events and play a primary role in the prevention of cardiovascular disease. At present,the secondary prevention status of aspirin for cardiovascular disease has been confirmed,and the primary prevention effect is still controversial. This article reviews the evidence of primary cardiovascular prophylaxis with aspirin in recent years,with a view to provide relevant reference for aspirin in clinical application

参考文献/References:

[1 ] U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events:recommendation and rationale[J]. Ann Intern Med,2002,136(2):157-160

[2 ] Gaziano JM,Brotons C,Coppolecchia R,et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease(ARRIVE):a randomised, double-blind, placebo-controlled trial[J]. Lancet,2018,392(10152):1036-1046.

[3 ] Ridker PM . Should aspirin be used for primary prevention in the post-statin era?[J]. N Engl J Med,2018,379(16):1572-1574.

[4 ] 黄秋瑾 , 胡蓉. 高血压合并糖尿病患者血压控制率和控制目标的探讨[J]. 心血管病学进展,2019,40(7):973-976.

[5 ] Buse JB,Ginsberg HN,Bakris GL,et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus:a scientific statement From the American Heart Association and the American Diabetes Association[J]. Circulation,2007,115(1):114-126.

[6 ] Zalewska J. Acetylsalicylic acid does not prevent progression of primary circulatory disorders in patients without symptoms of arterial disease and diabetesPOPADAD trial[J]. Kardio Pol,2009,67(2):213-214.

[7 ] Hebert PR,Schneider WR , Hennekens CH . Use of aspirin among diabetics in the primary prevention of cardiovascular disease:need for reliable randomized evidence and astute clinical judgment[J]. J Gen Intern Med,2009,24(11):1248-1250.

[8 ] Younis N,Williams S,Soran H. Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus[J]. Diabetes Obes Metab,2009,11(11):997-1000.

[9 ] Farkouh ME. ACP Journal Club.Aspirin and/or antioxidants did not prevent CV events in diabetes and peripheral arterial disease[J]. Ann Intern Med,2009,150(2):JC1-8.

[10 ] ASCEND Study Collaborative Group,Bowman L,Mafham M,et al. Effects of aspirin for primary prevention in persons with diabetes mellitus[J]. N Engl J Med,2018,379(16):1529-1539.

[11 ] McNeil JJ,Wolfe R,Woods RL,et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly[J]. N Engl J Med,2018,379(16):1509-1518.

[12 ] Ikeda Y,Shimada K,Teramoto T,et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors:a randomized clinical trial[J]. JAMA,2014,312(23):2510-2520.

[13 ] 程留芳. 老年上消化道出血临床特点及与药物相关性[C]. 中华医学会老年医学分会:中华医学会第四届全国老年消化专业学术会议论文集,2008:56-59.

[14 ] 陈夏欢,刘梅林,秦名芳,.小剂量阿司匹林对老年人血小板聚集率的影响和短期安全性评估 : 一项多中心随机对照临床研究[J]. 中华高血压杂志,2019,27(9):900.

[15 ] 2019 阿司匹林在心血管疾病一级预防中的应用中国专家共识写作组. 2019阿司匹林在心血管疾病一级预防中的应用中国专家共识 [J/OL]. 中华心血管病杂志(网络版),2019,2:e1000020 (2019-08-19).

[16 ] 胡盛寿,高润霖,刘力生,.《中国心血管病报告2018》概要[J]. 中国循环杂志,2019,34(3):209-220.

相似文献/References:

[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
 BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(6):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
 REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
 YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(6):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
 ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(6):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
 QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(6):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
 JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(6):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
 HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(6):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
 Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(6):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
 WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(6):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]

更新日期/Last Update: 2020-09-22